Profender

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

emodepside, praziquantel

Available from:

Vetoquinol S.A.

ATC code:

QP52AA51

INN (International Name):

emodepside, praziquantel

Therapeutic group:

Dogs; Cats

Therapeutic area:

Antiparazitni izdelki, insekticidi in repelenti

Therapeutic indications:

CatsFor mačke, ki trpijo ali na tveganje, mešani parazitske okužbe, ki jih povzročajo roundworms in tapeworms od naslednjih vrst:Roundworms (Nematodes)Toxocara cati (zrelih odraslih, nezreli odraslih, L4 in L3);Toxocara cati (L3 ličinke) – zdravljenje kraljice, v pozni nosečnosti, da se prepreči lactogenic prenos na potomce;Toxascaris leonina (zrelih odraslih, nezreli odraslih in L4);Ancylostoma tubaeforme (zrelih odraslih, nezreli odraslih in L4). Tapeworms (Cestodes)Dipylidium caninum (zrelih odraslih in nezreli za odrasle);Taenia taeniaeformis (za odrasle);Echinococcus multilocularis (za odrasle). LungwormsAelurostrongylus abstrusus (za odrasle). DogsFor psi, ki trpijo ali na tveganje, mešani parazitske okužbe, ki jih povzročajo roundworms in tapeworms od naslednjih vrst:Roundworms (nematodes):Toxocara canis (zrelih odraslih, nezreli odraslih, L4 in L3);Toxascaris leonina (zrelih odraslih, nezreli odraslih in L4);Ancylostoma caninum (zrelih odraslih in nezreli za odrasle);Uncinaria stenocephala (zrelih odraslih in nezreli za odrasle);Trichuris vulpis (zrelih odraslih, nezreli odraslih in L4);Tapeworms (Cestodes):Dipylidium caninum;Taenia spp. ;Echinococcus multilocularis (zrelih odraslih in nezreli);Echinococcus granulosus (zrelih odraslih in nezreli).

Product summary:

Revision: 19

Authorization status:

Pooblaščeni

Authorization date:

2005-07-27

Patient Information leaflet

                                62
B. NAVODILO ZA UPORABO
63
[Enoodmerna merilna kapalka]
NAVODILO ZA UPORABO
PROFENDER 30 MG/ 7.5 MG KOŽNI NANOS, RAZTOPINA ZA MAJHNE MAČKE
PROFENDER 60 MG/ 15 MG KOŽNI NANOS, RAZTOPINA ZA SREDNJE VELIKE
MAČKE
PROFENDER 96 MG/ 24 MG KOŽNI NANOS, RAZTOPINA ZA VELIKE MAČKE
1.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM TER
PROIZVAJALEC ZDRAVILA, ODGOVOREN ZA SPROŠČANJE SERIJ, ČE STA
RAZLIČNA
Imetnik dovoljenja za promet z zdravilom:
Vetoquinol S.A.
Magny-Vernois
70200 Lure
Francija
Proizvajalec odgovoren za sproščanje serij:
KVP Pharma + Veterinär Produkte GmbH
Projensdorfer Str. 324
24106 Kiel
Nemčija
2.
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI
Profender 30 mg/ 7.5 mg kožni nanos, raztopina za majhne mačke
Profender 60 mg/ 15 mg kožni nanos, raztopina za srednje velike
mačke
Profender 96 mg/ 24 mg kožni nanos, raztopina za velike mačke
Prazikvantel / Emodepsid
3.
NAVEDBA UČINKOVIN IN DRUGIH SESTAVIN
UČINKOVINE:
Zdravilo Profender vsebuje 21,4 mg/ml emodepsida in 85,8 mg/ml
prazikvantela.
Enota odmerka (merilna kapalka) zdravila Profender vsebuje:
ENOTA
EMODEPSID
PRAZIKVANTEL
Profender za majhne mačke
(≥ 0,5 – 2,5 kg)
0,35 ml
7,5 mg
30,0 mg
Profender za srednje velike mačke
(> 2,5 – 5 kg)
0,70 ml
15,0 mg
60,0 mg
Profender za velike mačke
(> 5 – 8 kg)
1,12 ml
24,0 mg
96,0 mg
POMOŽNE SNOVI:
5,4 mg/ml butilhidroksianizol (E 320 kot antioksidant)
4.
INDIKACIJE
64
Za mačke, ki imajo ali so izpostavljene mešanim parazitarnim
infekcijam z naslednjimi vrstami
valjastih črvov, trakulj in pljučnih črvov:
Valjasti črvi (Nematodi)
_Toxocara cati _(zrela odrasla oblika, nezrela odrasla oblika,
ličinke L4 in L3),
_Toxocara cati_ (ličinke L3) – zdravljenje mačk v obdobju pozne
brejosti, da se prepreči laktogeni
prenos na potomce,
_Toxascaris leonina _(zrela odrasla oblika, nezrela odrasla oblika,
ličinka L4),
_Ancylostoma tubaeforme _(zrela odrasla oblika, nezrela odrasla oblika
in ličinka L4).
Trakulje (Cestodi)
_Dipylidium caninum _(zrela odrasla in nezrela odr
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
_ _
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
[Enoodmerna merilna kapalka]
1.
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI
Profender 30 mg/ 7.5 mg kožni nanos, raztopina za majhne mačke
Profender 60 mg/ 15 mg kožni nanos, raztopina za srednje velike
mačke
Profender 96 mg/ 24 mg kožni nanos, raztopina za velike mačke
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
UČINKOVINE:
Zdravilo Profender vsebuje 21,4 mg/ml emodepsida in 85,8 mg/ml
prazikvantela.
Enota odmerka (merilna kapalka) zdravila Profender vsebuje:
ENOTA
EMODEPSID
PRAZIKVANTEL
Profender za majhne mačke
(≥ 0,5 – 2,5 kg)
0,35 ml
7,5 mg
30,0 mg
Profender za srednje velike mačke
(> 2,5 – 5 kg)
0,70 ml
15,0 mg
60,0 mg
Profender za velike mačke
(>5 – 8 kg)
1,12 ml
24,0 mg
96,0 mg
POMOŽNE SNOVI:
5,4 mg/ml butilhidroksianizol (E 320 kot antioksidant)
Za celoten seznam pomožnih snovi, glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
Kožni nanos, raztopina.
Bistra, rumena do rjavkasta raztopina.
4.
KLINIČNI PODATKI
4.1
CILJNE ŽIVALSKE VRSTE
Mačke
4.2
INDIKACIJE ZA UPORABO PRI CILJNIH ŽIVALSKIH VRSTAH
Za mačke, ki imajo ali so izpostavljene mešanim parazitarnim
infekcijam z naslednjimi vrstami
valjastih črvov, trakulj in pljučnih črvov:
Valjasti črvi (Nematodi)
_Toxocara cati _(zrela odrasla oblika, nezrela odrasla oblika,
ličinke L4 in L3)
_Toxocara cati_ (ličinke L3) – zdravljenje mačk v obdobju pozne
brejosti, da se prepreči laktogeni
prenos na potomce
_Toxascaris leonina _(zrela odrasla oblika, nezrela odrasla oblika in
ličinka L4)
_Ancylostoma tubaeforme _(zrela odrasla oblika, nezrela odrasla oblika
in ličinka L4)
3
Trakulje (Cestodi)
_Dipylidium caninum _(zrela odrasla in nezrela odrasla oblika)
_Taenia taeniaeformis _(odrasla oblika)
_Echinococcus multilocularis _(odrasla oblika)
Pljučni črvi:
_Aelurostrongylus abstrusus_ (odrasla oblika)
4.3
KONTRAINDIKACIJE
Zdravila ne dajemo mačjim mladičem mlajšim od 8 tednov in lažjim
od 0,5 kg.
Ne uporabite v primerih preobčutljivosti na učinkovine ali na katero
koli pom
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 25-01-2021
Summary of Product characteristics Summary of Product characteristics Bulgarian 25-01-2021
Public Assessment Report Public Assessment Report Bulgarian 06-06-2016
Patient Information leaflet Patient Information leaflet Spanish 25-01-2021
Public Assessment Report Public Assessment Report Spanish 06-06-2016
Patient Information leaflet Patient Information leaflet Czech 25-01-2021
Public Assessment Report Public Assessment Report Czech 06-06-2016
Patient Information leaflet Patient Information leaflet Danish 25-01-2021
Public Assessment Report Public Assessment Report Danish 06-06-2016
Patient Information leaflet Patient Information leaflet German 25-01-2021
Public Assessment Report Public Assessment Report German 06-06-2016
Patient Information leaflet Patient Information leaflet Estonian 25-01-2021
Public Assessment Report Public Assessment Report Estonian 06-06-2016
Patient Information leaflet Patient Information leaflet Greek 25-01-2021
Public Assessment Report Public Assessment Report Greek 06-06-2016
Patient Information leaflet Patient Information leaflet English 25-01-2021
Public Assessment Report Public Assessment Report English 06-06-2016
Patient Information leaflet Patient Information leaflet French 25-01-2021
Public Assessment Report Public Assessment Report French 06-06-2016
Patient Information leaflet Patient Information leaflet Italian 25-01-2021
Public Assessment Report Public Assessment Report Italian 06-06-2016
Patient Information leaflet Patient Information leaflet Latvian 25-01-2021
Public Assessment Report Public Assessment Report Latvian 06-06-2016
Patient Information leaflet Patient Information leaflet Lithuanian 25-01-2021
Summary of Product characteristics Summary of Product characteristics Lithuanian 25-01-2021
Public Assessment Report Public Assessment Report Lithuanian 06-06-2016
Patient Information leaflet Patient Information leaflet Hungarian 25-01-2021
Summary of Product characteristics Summary of Product characteristics Hungarian 25-01-2021
Public Assessment Report Public Assessment Report Hungarian 06-06-2016
Patient Information leaflet Patient Information leaflet Maltese 25-01-2021
Public Assessment Report Public Assessment Report Maltese 06-06-2016
Patient Information leaflet Patient Information leaflet Dutch 25-01-2021
Public Assessment Report Public Assessment Report Dutch 06-06-2016
Patient Information leaflet Patient Information leaflet Polish 25-01-2021
Public Assessment Report Public Assessment Report Polish 06-06-2016
Patient Information leaflet Patient Information leaflet Portuguese 25-01-2021
Summary of Product characteristics Summary of Product characteristics Portuguese 25-01-2021
Public Assessment Report Public Assessment Report Portuguese 06-06-2016
Patient Information leaflet Patient Information leaflet Romanian 25-01-2021
Public Assessment Report Public Assessment Report Romanian 06-06-2016
Patient Information leaflet Patient Information leaflet Slovak 25-01-2021
Public Assessment Report Public Assessment Report Slovak 06-06-2016
Patient Information leaflet Patient Information leaflet Finnish 25-01-2021
Public Assessment Report Public Assessment Report Finnish 06-06-2016
Patient Information leaflet Patient Information leaflet Swedish 25-01-2021
Public Assessment Report Public Assessment Report Swedish 06-06-2016
Patient Information leaflet Patient Information leaflet Norwegian 25-01-2021
Summary of Product characteristics Summary of Product characteristics Norwegian 25-01-2021
Patient Information leaflet Patient Information leaflet Icelandic 25-01-2021
Summary of Product characteristics Summary of Product characteristics Icelandic 25-01-2021
Patient Information leaflet Patient Information leaflet Croatian 25-01-2021
Public Assessment Report Public Assessment Report Croatian 06-06-2016

Search alerts related to this product

View documents history